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Autoantibodies associated with the subepidermal blistering 
disorders bullous pemphigoid and herpes gestationis react 
with a 180-kD transmembrane hemidesmosomal protein, 
designated BP180. The BP180 ectodomain is composed of a 
series of interrupted collagen triple helical domains. Lo-
cated on one of the noncollagenous extracellular segments of 
this protein is an immunodominant epitope, designated 
MCW -1, recognized by patient autoantibodies. In this in-
vestigation we have developed an enzyme-linked immuno-
sorbent assay system to detect antibody reactivity against 
the M CW -1 epitope with the use of a bacterial fusion pro-
tein containing the BP180 autoantibody-reactive site. The 
following sera were assayed for reactivity with this recombi-
nant protein: bullous pemphigoid (n = 62), herpes gesta-
tionis (n = 28), endemic pemphigus foliaceus (n = 17), 
lupus erythematosus (n = 15), and normal human sera (n = 
B ullous pemphigoid (BP) and herpes gestationis (HG) are autoimmune skin diseases that are characterized by the presence of subepidermal blisters resulting from detachment of basal keratinocytes from the dermis through a plane of cleavage located at the lamina lu-
cida. The most consistent immunopathologic finding in both BP 
and HG is the detection oflinear deposits of C3 along the cutaneous 
basement membrane zone of perilesional skin [1]. Immunoglobulin 
(Ig)G class autoantibodies directed against basement membrane 
zone antigens are also frequently found in perilesional skin and in 
the sera of BP patients [1- 3]. In contrast, both tissue-bound and 
circulating autoantibodies are rarely detectable in HG patients using 
standard direct or indirect immunofluorescence (IF) techniques. 
The more sensitive complement fixation assay is typically used to 
detect low-titer circulating anti-basement membrane zone autoan-
tibodies, also known as "HG factor," in these patients [4,5). 
Recently, significant advances have been made in the molecular 
characterization of the major antigen/antibody systems associated 
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22). This enzyme-linked immunosorbent assay - based pro-
tocol was shown to be highly specific (98.3%) in detecting 
autoantibody activity in bullous pemphigoid and herpes ges-
tationis patients. Fifty-three percent of bullous pemphigoid 
sera and 71% of herpes gestationis sera, but none of the 
control sera, yielded positive results in this assay. Of the 
patient sera that were known to react with full-length 
BP180, almost all showed reactivity with the MCW-1 anti-
genic site of this protein. Autoantibodies detected in this 
assay were predominantly of the immunoglobulin G class. 
The results presented here lend support to the hypothesis that 
this well-defined antigen/antibody system may be relevant 
in pathogenesis. Key words: hemidesmosome/autoimmunity/ 
skin/basement membrane/collagen. ] Invest Dermatol 102:878-
881,1994 
with these autoimmune disorders. Autoantibodies from BP and HG 
sera have been shown to recognize two epidermal hemidesmosomal 
antigens, BP180 and BP230 [6-14] . BP230 is a major constituent 
of the intracellular hemidesmosomal plaque [15] and exhibits ho-
mology with desmosomal plaque components [16,17]. The BP180 
antigen, in contrast, has been identified as a putative transmembrane 
glycoprotein with a long, carboxyl-terminal collagenous domain 
[14,18]. Recent ultrastructural localization studies have confirmed 
that the amino terminus of BP180 is restricted to the intracellular 
plaque of the hemidesmosome [19], whereas the carboxyl-terminal 
half projects into the lamina lucida [20]. An epitope mapping analy-
sis has revealed that both BP and HG sera react with a single im-
munodominant antigenic site, designated MCW-1, located within 
the BP180 NC16A domain, the major noncollagenous stretch of 
the extracellular domain of this protein [20]. 
In the present study we have developed an enzyme-linked im-
munosorbent assay (ELISA) to facilitate the identincation and fur-
ther characterization of autoantibodies directed against the BP180 
MCW -1 antigenic site. Autoantibodies detected in this assay were 
shown to be a highly specific marker for BP and HG. Thus, this 
assay may have diagnostic value and should aid in the study of the 
pathogenic relevance of this antigen/antibody system. 
MATERIALS AND METHODS 
Sera Serum samples were obtained from patients with BP (n = 62), HG 
(n = 28), endemic pemphigus foliaceous (EPF; n = 17) and lupus erythem-
atosus (LE; n = 15) and from normal controls (NHS; n = 22). Fifty-eight of 
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Figure 1. Schematic diagram of the protein domain organization of the 
BP180 antigen. BP180 is a transmembrane protein with a type II orienta-
tion. The transmembrane domain is represented by the gray rectangle. The 
carboxyl-terminal 931 amino acids of BP180 comprise a collagenous tail 
made up of a series of interrupted collagen triple helical domains (solid 
rectangles). The BP /HG autoantibody-reactive site is represented by the opel/ 
ova /located within a noncollagenous extracellular domain. The 42-amino-
acid stretch ofBP180 that is contained within the GST -S~l fusion protein is 
indicated by the segment designated BP180-S~1. 
the 62 BP sera contained circulating autoantibodies to the basement mem-
brane zone, as determined by indirect IF. Nineteen of the 28 HG sera used in 
this study were positive for the "HG factor," as determined by complement 
fixation analysis. All sera from EPF patients showed staining of the epider-
mal intercellular spaces by indirect IF analysis. Lupus patients were selected 
at random from a group with definitive clinical identification and at least one 
positive autoantibody test (direct immunofluorescence, anti-nuclear anti-
body, anti-SSA, anti-SSB, anti-Sm, or nRNP antibodies). Patient and normal 
sera were stored frozen at - 20 0 C prior to analysis. 
Preparation of Recombinant Proteins A segment of a human cONA 
encoding a 42 - amino-acid stretch of the BP180 antigen was subcloned into 
the prokaryotic expression vector pGEX-2T (Pharmacia LKB Biotechnol-
ogy, Piscataway, NJ). The resulting glutathione S-transferase (GST)-BP180 
fusion protein, GST-S~1 (see Fig 1) and recombinant GST encoded by 
pGEX-2T were expressed in Escherichia coli (Strain OH5a) and purified as 
described previously [20-22] . 
ELISA All incubations and washes in this assay were conducted at room 
temperature. The recombinant proteins GST-S~1 and GST were immobil-
ized on 96-well polystyrene plates (1.7/lg/well) by incubation at room 
temperature for 2 h. Wells were washed five times with 0.05% Tween-20 in 
phosphate-buffered salin~ (PBS), then blocked with 1 % bovine serum albu-
min (BSA)/PBS for 30 mm. After repeatmg the wash, sera from patients and 
controls (diluted 1 : 100 in 1 % BSA, 1 % Tween in PBS) were added to each 
well and incubated for 30 min. On every ELISA plate used in this study, the 
same positive control (BP serum, Rus) and negative control serum (NHS-
AT) were included as internal standards. After washing again as above, one 
of the following secondary antibody preparations was added to each well and 
incubated for 1 h, followed by a final wash step. Horseradish peroxidase-la-
beled goat antibody directed against human IgA/IgG/lgM (Kirkegaard and 
Perry, Gaithersburg, MO) was used at a 1: 1000 dilution in 1 % BSA/PBS. 
Horseradish peroxidase-conjugated goat antibodies that specifically recog-
nize human IgG, IgM, IgA, or IgE (Kirkegaard and Perry) were used at the 
working dilutions suggested by the manufacturer. The substrate solution, 
containing o-phenylenediamine in 0.03% H20 2 , was then added to each 
wel l. When the positive control reaction reached an optical density (00) at 
492 nm of approximately 1 U, as determined by comparison with standards, 
the reactions were stopped with 2N H2SO •. The 00'92 of the solution in 
each well was then measured using a microplate reader (model 2550; Bio-
Rad, Richmond, CAl. Each of the primary sera was assayed in duplicate and 
the 00 value corresponding to the level of reactivity with GST was sub-
tracted from the value obtained with GST-S~1. All raw data were then 
standardized based on the results of the positive and negative internal stan-
dards, which were set to 1 and 0 00 units, respectively. 
Statistical Analyses The ELISA results obtained from the three control 
groups of sera (EPF, LE, and NHS) were normalized using the Box-Cox 
transformation [23]. The transformed data were used to compute the speci-
ficity of the ELISA. The data obtained from the HG group of sera were 
analyzed using the kappa statistic [24] as a measure of the concordance 
between the ELISA and complement fixation assays. 
RESULTS 
Autoantibodies from Both BP and HG Sera Recognize GST-
Sdl by ELISA The BP180 fusion protein GST-Sill was immo-
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Figure 2. Scatter plot representation of ELISA results. Patient and control 
sera (as indicated along the horizolltai axis) were incubated with immobilized 
BP180-S.1.1 and the bound antibodies were detected with a horseradish 
peroxidase-conjugated antibody against human IgG/lgM/lgA. Each sample 
was run in duplicate and the points plotted on this graph represent the 
difference of the averages of the 00'92 readings obtained with immobilized 
BP180-S~1 and recombinant GST. 
NBS. Bound immunoglobulin was detected with a horseradish 
peroxid~se-conjugated goat-anti-human IgA/lgG/lgM antibody 
preparation. The results of this analysis are displayed on a scatter 
plot shown in Fig 2. The results from the negative control sera were 
analyzed to determine an appropriate cut-off value for this assay. As 
seen in Fig 2, every sera in the three control groups (EPF, LE, and 
NHS) showed very low levels of reactivity in this assay, with stan-
dardized values ranging from - 0.09 to 0.13 OD units (a standard-
ized value below 0 indicates that the serum exhibited a slightly 
~ower level of.reactivity with GST -Sill compared with that of the 
mternal negative control). A one-way analysis of variance showed 
no significant difference in the mean 00492 values obtained from ~he three groups of control sera. The Shapiro-Wilk test for normal-
Ity [25] demonstrated that the observed data from the three individ-
ual control groups, as well as the pooled data from these groups, 
showed a good fit with the theoretical normal distribution. Based 
on. the Box-Cox transformations [23] of the control data, it was 
estimated that 98.3% of all control sera would yield results below 
0.14500 units. Using this value as the threshold for the ELISA 
(dotted horizontaffine in Fig 2), it was determined that 33 of 62 BP 
se~a (53%) and 20 of 28 BG sera (71 %) exhibited specific reactivity 
WIth the GST-Sill fusion protein. Decreasing the threshold value 
below 0 .. 145.00 units resulted in a decrease in the specificity of the 
assay, With ltttle change in the sensitivity. 
The ELISA results were further analyzed to determine whether 
th.ey cor~elated with indirect IF and immunoblotting results ob-
tamed WIth BP sera. As documented in Table I 58 of the 62 BP sera ~sed in. thi.s study showed positive basement ~embrane zone stain-
mg by mdlre~t.IF. Thirty-two of these indirect IF-positive BP sera 
were als~ posItIve by ELISA against GST -Sill. Of the four indirect 
IF-negattve BP ser~, o~e yielded a positive ELISA result. Figure 3 
shows a plot of the mdlrect IF titer and ELISA results obtained with 
BP sera. There was no significant correlation between the results of 
these two assays (correlation = 0.12, P = 0.25). In contrast, there 
was good agreement between the GST-Sill ELISA and BP180 im-
munoblotting results (Ie = 0.79, P < 0.005). The kappa value can 
Table I. Comparison of BP Sera Results Obtained by GST-Sill 
ELISA and Indirect Immunofluorescence Analysis on 
Normal Human Skin 
Indirect IF Analysis 
Positive' Negative Total 
ELISA (positive) 32 1 33 
ELISA (negative) 26 3 29 
Total 58 4 62 
• Indicates indirect IF staining of the cutaneous basement membrane zone. 
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Figure 3. A plot of the indirect IF titer versus the GST -S1l.1 ELISA results 
for BP sera. The indirect IF titer using normal human skin as substrate 
(horizontal axis) and ELISA result (vertical axis) for each of the 62 BP sera 
used in this study was plotted. No correlation between these two immuno-
logic activities was found. 
vary from 1 (indicating complete agreement between the two pa-
rameters being tested) to 0 (indicating complete disagreement). 
Nineteen of the 62 BP sera used in this study were selected at 
random and analyzed by immunoblot for BP180 reactivity using a 
human epidermal total protein extract. As shown in Table II, 63% 
of these BP sera (12 of 19) were positive by ELISA and 53% (10 of 
19) were positive by immunoblot. Fifteen of the 19 sera showed 
agreement in these two assays (nine sera were positive by both 
ELISA and immunoblot and six were negative by both assays). 
The results from the GST-Sill ELISA and the complement fixa-
tion assay for "HG factor" were compared for each of the HG sera 
used in this study and the results are displayed in Table III. Results 
from 19 of the 28 HG sera showed agreement between these two 
assays, i.e., 15 HG sera were positive by both assays and four yielded 
negative results in both assays; however, the kappa statistic showed 
marginal concordance (K = 0.68; p = 0.1). 
BP and HG Autoantibodies That Recognize GST -Sill are 
Predominantly of the IgG Class The reactivity ofBP and HG 
sera with GST -Sill was further characterized by ELISA using sec-
ondary antibodies specific for human IgG, IgM, IgA, or IgE. The 
results of this analysis are displayed as scatter plots in Fig 4. In 32 of 
32 BP sera tested (100%) and in nine of nine HG sera (100%) 
anti-GST-Sill reactivity was shown to be mediated by IgG class 
immunoglobulins. None of the BP or HG sera contained detectable 
levels of IgA, IgE, or IgM that reacted with GST-Sill by ELISA. 
DISCUSSION 
A highly specific ELISA-based protocol has been developed for 
detecting reactivity ofBP and HG sera with BP180-Sill, a recom-
binant protein containing a 42 - amino-acid noncollagenous stretch 
(NC16A) of the BP180 ectodomain. Overall, 33 of 62 BP sera 
Table II. Comparison of BP Sera Results Obtained by 
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Table m. Comparison of HG Sera Results Obtained by 
GST -Sill ELISA and Complement-Fixation Assay 
Complement-Fixation Assay 
Positive' Negative Total 
ELISA (positive) 15 5 20 
ELISA (negative) 4 4 8 
Total 19 9 28 
" Indicates staining of the cutaneous basement membrane zone. 
(53%) and 20 of 28 HG sera (71 %) showed reactivity with this 
antigenic site. A large sampling of control sera (including EPF, LE, 
and NHS) were tested for reactivity with BP180-Sill, and none 
yielded results above the threshold value established for this assay. 
The specificity of this ELISA was calculated to be 98.3%. . 
A comparison of the GST -Sill ELISA and immunoblot analysIs 
using an epidermal extract showed a good correlation between. these 
two assays in detecting anti-BP180 activity in patient sera. NlI~e of 
ten BP sera (90%) that reacted with the full -length BP180 antigen 
on an immunoblot showed reactivity with the Sill segment of 
BP180 by ELISA. Three of 19 BP sera (16%) that were positive by 
the GST-Sill ELISA showed no BP180 reactivity by immunoblot. 
The discrepancies in the results obtained by these two assays can be 
accounted for in one of the following ways: 1) the ELISA may be 
more sensitive than the immunoblot assay in detecting antibody 
activity against the Sill stretch ofBP180, 2) an autoantibody-reac-
tive epitope that is present on GST -Sill fusion protein under the 
conditions of the ELISA may be destroyed under the conditions of 
the immunoblot assay, or 3) some BP sera may react with BP180 at a 
site outside the Sill stretch. Relevant to the last point, one BP serum 
used by Hopkinson et al [19] was shown to react with the intracellu-
lar domain of the BP180 antigen. 
It is well established that the humoral autoimmune response in 
BP patients is polyclonal and multispecific. In addition to th.e 
BP180 antigen, a second hemidesmosomal comronent, BP230, IS 
recognized by a high percentage ofBP sera [6,26 . Other epidermal 
antigens, yet to be fully characterized, may also act as targets of BP 
autoantibodies [8,27,28]. Because of the heterogeneous nature of 
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Figure 4_ Immunoglobulin class restriction of the anti - GST -SL'i t response 
in BP and HG patients. BP sera (top parlel) and HG sera (bottom panel) were 
incubated with immobilized GST-Sll.1, then probed with one of a series of 
horseradish peroxidase-conjugated antibodies specific for each of the human 
Ig classes (as indicated on the 'IOrizontal axes). Each assay was run in duplicate 
and the resulting values plotted on these graphs were calculated as described 
in Fig 2 . 
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the BP autoimmune response, it was not surprising to discover that 
indirect IF titers of BP sera did not show a direct correlation with 
the results of the GST -S~ 1 ELISA. Indirect IF staining characteris-
tics presumably reflect a composite pattern of the various specifici-
ties displayed by BP autoantibodies, whereas the ELISA protocol 
detects only that subset ofBP autoantibodies directed against a short 
segment of the BP180 ectodomain. 
The humoral autoimmune response in HG patients was analyzed 
using two immunologic techniques. The complement fixation 
assay was used to detect complement-fixing autoantibodies in the 
sera of HG patients and the GST-S~1 ELISA was used to detect 
reactivity with the BP /HG antigenic site on the BP180 ectodo-
main. A majority of the cases (19 of 28 HG sera) exhibited concor-
dant results in these two assays; however, statistical analysis of the 
data showed only marginal concordance. It is possible that the pa-
rameters being measured by the ELISA and complement fixation 
assays are closely related, but failed to show a statistically significant 
level of concordance due simply to sample size. On the other hand, 
the discrepancies between the results of these two assays that were 
observed in nine of28 cases might be an indication of heterogeneity 
in the autoimmune response of HG patients, e.g., reactivity against 
multiple sites on the BP180 antigen or against multiple antigens. 
However, there is as yet no clear documentation of such phenomena 
in patients with HG. This issue will be addressed in future studies 
involving the immunologic analysis of HG sera following adsorp-
tion with various recombinant forms of BP180. 
Reactivity ofBP and HG sera with the GST -Sd 1 fusion protein as 
detected by ELISA is mediated predominantly by IgG class immu-
noglobulins. No IgA, IgE, or IgM was detected by the ELISA 
method. Elevated levels of immunoglobulins, other than the IgG 
class, have been reported in patients with these disorders [29 - 31]; 
however, the relevance of these findings remains unclear. Future 
studies aimed at determining the IgG subclass breakdown of the 
anti-BP180 reactivity should shed additional light on the role of 
autoantibodies with this antigenic specificity in complement activa-
tion. 
The results of this study have confirmed and extended a previous 
finding from our laboratory that BP and HG autoantibodies recog-
nize a common antigenic site, designated MCW-l, on the BP180 
antigen [20]. The MCW -1 autoantibody-reactive site was shown to 
be situated on the extracellular domain of the BP180 antigen, pro-
jecting into the cutaneous basal lamina [20]. Circulating autoanti-
bodies were predicted to have access to this well-defined immuno-
dominant site and were hypothesized to play an initiatory role in 
subepidermal blister formation . Support for this hypothesis has 
come from a recent study from our laboratory in which anti-BPl80 
antibodies were assayed for pathogenicity by passive transfer into 
neonatal BALB/c mice. Antibodies directed against the stretch of 
murine BP180 containing the MCW-1-homologous site were ef-
fective in inducing a subepidermal blistering disease in the injected 
animals that closely mimicked BP and HG [32]. 
The ELISA protocol presented in this report provides a conve-
nient and sensitive means by which autoantibodies directed against 
the MCW -1 antigenic site can be detected and further character-
ized. The specific subset of autoantibodies present in the sera of BP 
and HG patients that are detected in this assay represent a highly 
specific diagnostic disease marker. This system can be used to deter-
mine whether this autoantibody activity correlates with the extent 
or level of activity of disease. Such an approach should provide 
further insight into the pathogenic relevance of this antigen/anti-
body system. 
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